DBG
ISEE

De Burlo Group’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

De Burlo Group’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-21,700
Closed -$1.7M – 104
2015
Q4 		$1.7M Buy
+21,700
New +$1.25M 0.4% 63

Other funds holding ISEE

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JCG
JHL Capital Group Chicago, Illinois $805M AUM 50.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

De Burlo Group's ISEE Position: Q1 2016 in Review

De Burlo Group sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2016, closing a stake of 21,700 shares — an estimated $1.7M sold.

De Burlo Group first reported a position in ISEE in Q4 2015 and held it in 1 quarter. The position peaked at $1.7M in Q4 2015. 162 funds tracked by Wall St. Rank hold ISEE as of Q1 2016.

  • De Burlo Group reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • De Burlo Group sold 21,700 IVERIC bio, Inc. Common Stock shares in Q1 2016, an estimated $1.7M.
  • De Burlo Group first reported a position in IVERIC bio, Inc. Common Stock in Q4 2015 and held it in 1 quarter.
  • De Burlo Group's IVERIC bio, Inc. Common Stock position peaked at $1.7M in Q4 2015.
  • 162 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2016.

Based on De Burlo Group's 13F filing for Q1 2016, filed 5 May 2016.